{"DataElement":{"publicId":"6029554","version":"1","preferredName":"Intrathecal Route of Administration Therapeutic Procedure Administered Type","preferredDefinition":"A description of the intrathecal therapy that was administered.","longName":"2763950v1.0:6029542v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2763950","version":"1","preferredName":"Intrathecal Route of Administration Therapeutic Procedure Administered","preferredDefinition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._The act of having given something (e.g., a medication or test).","longName":"INT_ADM_TP_ADM","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2763948","version":"1","preferredName":"Intrathecal Route of Administration Therapeutic Procedure","preferredDefinition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C38267:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5196CE42-930A-69B2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-09","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-07-09","modifiedBy":"ONEDATA","dateModified":"2008-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5196CE42-9318-69B2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-09","endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-07-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6029542","version":"1","preferredName":"Intrathecal Therapeutic Procedure Type","preferredDefinition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Something distinguishable as an identifiable class based on common qualities.","longName":"6029542v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Intrathecal cytarabine","valueDescription":"Intrathecal Route of Administration Cytarabine","ValueMeaning":{"publicId":"5944543","version":"1","preferredName":"Intrathecal Route of Administration Cytarabine","longName":"5944543","preferredDefinition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.: A drug used to treat certain types of leukemia and prevent the spread of leukemia to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. Cytarabine blocks tumor growth by stopping DNA synthesis. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E8C4AF-0260-0B04-E053-F662850AE020","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E3065CB-C8E1-6527-E053-F662850A3FF7","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-17","modifiedBy":"ONEDATA","dateModified":"2017-11-17","deletedIndicator":"No"},{"value":"Intrathecal depo-cytarabine","valueDescription":"Intrathecal Route of Administration Liposomal Cytarabine","ValueMeaning":{"publicId":"5944542","version":"1","preferredName":"Intrathecal Route of Administration Liposomal Cytarabine","longName":"5944542","preferredDefinition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.: A liposomal intrathecal formulation of the antimetabolite cytarabine. As an S-phase-specific antimetabolite, cytarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; the incorporation of cytarabine triphosphate into DNA appears to inhibit DNA polymerase and so DNA synthesis, resulting in cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Liposomal Cytarabine","conceptCode":"C2388","definition":"A liposomal intrathecal formulation of the antimetabolite cytarabine. As an S-phase-specific antimetabolite, cytarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; the incorporation of cytarabine triphosphate into DNA appears to inhibit DNA polymerase and so DNA synthesis, resulting in cell death. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E8C4AF-023A-0B04-E053-F662850AE020","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E3065CB-C8EB-6527-E053-F662850A3FF7","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-17","modifiedBy":"ONEDATA","dateModified":"2017-11-17","deletedIndicator":"No"},{"value":"Intrathecal methotrexate","valueDescription":"Intrathecal Route of Administration Methotrexate","ValueMeaning":{"publicId":"3629881","version":"1","preferredName":"Intrathecal Route of Administration Methotrexate","longName":"3629881","preferredDefinition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.: An antimetabolite with antineoplastic and immunomodulating properties.  Methotrxate inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEF54A49-4B20-0AB2-E040-BB89AD431994","latestVersionIndicator":"Yes","beginDate":"2012-11-20","endDate":null,"createdBy":"KNUTSOND","dateCreated":"2012-11-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E3065CB-C8F5-6527-E053-F662850A3FF7","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-17","modifiedBy":"ONEDATA","dateModified":"2017-11-17","deletedIndicator":"No"},{"value":"Intrathecal methylprednisolone","valueDescription":"Intrathecal Route of Administration Methylprednisolone","ValueMeaning":{"publicId":"5944541","version":"1","preferredName":"Intrathecal Route of Administration Methylprednisolone","longName":"5944541","preferredDefinition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.: A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Methylprednisolone","conceptCode":"C647","definition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E8C4AF-0214-0B04-E053-F662850AE020","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E3065CB-C8FF-6527-E053-F662850A3FF7","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-17","modifiedBy":"ONEDATA","dateModified":"2017-11-17","deletedIndicator":"No"},{"value":"Intrathecal rituximab","valueDescription":"Intrathecal Route of Administration Rituximab","ValueMeaning":{"publicId":"5944540","version":"1","preferredName":"Intrathecal Route of Administration Rituximab","longName":"5944540","preferredDefinition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E8C4AF-01EE-0B04-E053-F662850AE020","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E3065CB-C909-6527-E053-F662850A3FF7","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-17","modifiedBy":"ONEDATA","dateModified":"2017-11-17","deletedIndicator":"No"},{"value":"Other intrathecal therapy","valueDescription":"Other Intrathecal Route of Administration Therapeutic Procedure","ValueMeaning":{"publicId":"5944539","version":"1","preferredName":"Other Intrathecal Route of Administration Therapeutic Procedure","longName":"5944539","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E8C4AF-01B4-0B04-E053-F662850AE020","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62982504-9359-4EB1-E053-F662850AAA82","beginDate":"2017-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-01-12","modifiedBy":"ONEDATA","dateModified":"2018-01-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6029541","version":"1","preferredName":"Intrathecal Route of Administration Therapeutic Procedure Type","preferredDefinition":"Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Something distinguishable as an identifiable class based on common qualities.","longName":"C38267:C49236:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E3065CB-C8A6-6527-E053-F662850A3FF7","latestVersionIndicator":"Yes","beginDate":"2017-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-17","modifiedBy":"ONEDATA","dateModified":"2017-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E3065CB-C8B7-6527-E053-F662850A3FF7","latestVersionIndicator":"Yes","beginDate":"2017-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-17","modifiedBy":"NYCHM","dateModified":"2018-02-12","changeDescription":".; Updated PV \"Other IT Therapy\" per OK to do so.  AK 1/102/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"LYMpre_thrpym_it_thrpy_drug_ty","type":"NMDP_FN","context":"NHLBI"},{"name":"LYMpost_OT_it_thrpy_drug_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the intrathecal ther","type":"Preferred Question Text","description":"What was the intrathecal therapy that was administered?","url":null,"context":"NHLBI"},{"name":"Specify intrathecal therapy","type":"Alternate Question Text","description":"Specify intrathecal therapy","url":null,"context":"NHLBI"},{"name":"Specify intrathecal therapy","type":"Application Standard Question Text","description":"Specify intrathecal therapy","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E318422-0CC9-31E2-E053-F662850A749C","latestVersionIndicator":"Yes","beginDate":"2017-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-17","modifiedBy":"NYCHM","dateModified":"2018-02-12","changeDescription":".; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}